Lanean...
Recent developments in limited stage small cell lung cancer
Limited stage small cell lung cancer (LS-SCLC) remains a challenging disease, with 5-year overall survival ranging from 30–35% with current standard of care treatment consisting of thoracic radiation to 45 Gy in 30 fractions delivered twice daily, with concurrent platinum/etoposide chemotherapy, fol...
Gorde:
| Argitaratua izan da: | Transl Lung Cancer Res |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6795581/ https://ncbi.nlm.nih.gov/pubmed/31673519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.05.13 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|